Ketotifen Capsules: 0.25mg, 0.5mg, 1mg, 2mg
Ketotifen is a second generation H1 antihistamine often recommended by prescribers for the treatment of asthma and allergies. Oral Ketotifen has been used in Europe, Canada, and Mexico for patients with asthma, chronic urticaria, allergic rhinitis, and other conditions.  In the U.S., ketotifen has been approved for ocular administration in the treatment of allergic conjunctivitis. Recently, ketotifen oral compounded capsules have been recommended to address symptoms of mast cell activation syndrome (MCAS) associated with chronic inflammatory response syndrome (CIRS), Mold/Biotoxin Illness, Lyme disease, and chronic urticaria.  Patients with chronic inflammatory response syndrome (CIRS) often report symptoms of mast cell activation syndrome as well (MCAS). MCAS occurs when a patient’s mast cells are working to fight off a foreign substance in the body by frequently overproducing histamine, a hormone that causes allergy symptoms such as inflammation. Ketotifen relieves symptoms caused by the overproduction of histamines in the body by stabilizing the mast cell and inhibiting the release of its proinflammatory mediators.  Ketotifen oral capsules are not commercially available in the U.S. and must be compounded through a compounding pharmacy.
Ketotifen has been found to be helpful for patients with:
- Mast Cell Activation Syndrome (MCAS)
- Chronic Inflammatory Response Syndrome (CIRS)
- Mold/Biotoxin Illness
- Lyme Disease
- Chronic Urticaria
- Crohn’s Disease
- And many more…
The Mechanism of Allergy:
Please contact our clinical department today at (805) 427-9053 and ask to speak with one of our expert chronic inflammatory response syndrome (CIRS), mold/biotoxin illness, MCAS, and Lyme Disease clinical pharmacists about Ketotifen oral capsules.
 Sokol, K. C., Amar, N. K., Starkey, J., & Grant, J. A. (2013). Ketotifen in the management of chronic urticaria: the resurrection of an old drug. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 111(6), 433–436. https://doi.org/10.1016/j.anai.2013.10.003
 Kamide R, Niimura M, Ueda H, Imamura S, Yamamoto S, Yoshida H, Kukita A. Clinical evaluation of ketotifen for chronic urticaria: a multicenter double-blind comparative study with clemastine. Ann Allergy. 1989 Apr;62(4):322-5. PMID: 2650586.
 Sokol, K. C., Amar, N. K., Starkey, J., & Grant, J. A. (2013). Ketotifen in the management of chronic urticaria: the resurrection of an old drug. https://doi.org/10.1016/j.anai.2013.10.003